Immunogenicity of therapeutic proteins

14Citations
Citations of this article
24Readers
Mendeley users who have this article in their library.
Get full text

Abstract

The era of the medical application of proteins started at the end of the nineteenth century when animal sera were introduced for the treatment of serious complications of infections such as diphtheria and tetanus. The high doses used, the general lack of quality controls and a regulatory system, and the impurity of the preparations led to many serious and sometimes even fatal side effects. Many of the problems were caused by the strong immune response these foreign proteins induced, especially when readministered. People who had been treated in general had a warning in their passports or identification cards to alert physicians for a possible anaphylactic reaction after rechallenge with an antiserum. Also serum sickness caused by deposits of antigen-antibody complexes was a common complication of the serum therapy.

Cite

CITATION STYLE

APA

Schellekens, H., & Jiskoot, W. (2013). Immunogenicity of therapeutic proteins. In Pharmaceutical Biotechnology: Fundamentals and Applications, Fourth Edition (pp. 133–141). Springer New York. https://doi.org/10.1007/978-1-4614-6486-0_6

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free